Urinary diagnostic proteomic markers for dynapenia in cancer patients

Holger Husi, Alisdair MacDonald, Richard J.E. Skipworth, Janice Miller, Andrew Cronshaw, Carolyn Greig, Kenneth C.H. Fearon, James A. Ross

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)
117 Downloads (Pure)


Dynapenia is defined as the age‑related loss of muscle strength, and plays a significant role in the loss of physical function and increased risk of disability among older individuals. The need for an early diagnosis supports the search for a biomarker that reflects muscle ‘weakening’. This has previously proven difficult due to patient heterogeneity at presentation and lack of understanding of the underlying molecular mechanisms. The aim of the present study was to identify potential urinary biomarkers of dynapenia in patients undergoing potentially curative surgery for upper gastrointestinal cancer. Maximum isometric knee extensor strength (strain gauge) and maximum leg extensor power (Nottingham power rig) measurements were taken. Cut‑off values for dynapenia were based on the Allied Dunbar national fitness survey. Values below the 5th percentile for the population matched for age and sex on the Allied Dunbar national fitness survey were used to stratify the cohort into dynapenic or normal. Urine samples taken at induction of anaesthesia were analysed by SELDI‑TOF mass spectrometry using CM10 and IMAC30 chip‑types to establish statistically significant m/z peak fingerprint patterns, followed by in‑gel LC‑MS/MS to identify molecular constituents. Statistical analysis of decision‑tree calculations using Biomarker Pattern software resulted in models with sensitivities of 86 and 96%, specificities of 81 and 89%, and overall correctness of 84 and 93%, when applied to the entire cohort for power and strength measurement‑based stratifications using the IMAC30 chip‑type and the CM10 chip‑type, respectively. The molecular identities of 10 peaks of interest were further investigated. After subtraction of potentially unrelated proteins, they were identified as fragments of Annexin A1, collagen α‑1 (XV), perlecan and myotrophin. These results demonstrate that urinary screening can be used to define cancer‑associated muscle weakness, and the identification of potential biomarkers could be invaluable in establishing a rapid test to measure and assess dynapenia in the clinical setting.
Original languageEnglish
Pages (from-to)547-556
Number of pages10
JournalBiomedical Reports
Issue number6
Publication statusPublished - 25 Apr 2018


  • dynapenia
  • muscle wasting
  • urine biomarker


Dive into the research topics of 'Urinary diagnostic proteomic markers for dynapenia in cancer patients'. Together they form a unique fingerprint.

Cite this